Lifecome Biochemistry Co.,Ltd. (SHE:002868)
China · Delayed Price · Currency is CNY 37.93
+0.63 (1.69%)
At close: Feb 13, 2026
Lifecome Biochemistry Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 548.35 | 610.68 | 489.93 | 308.72 | 343.29 | 307.62 |
Other Revenue | 38.69 | 38.69 | 17.07 | 21.14 | 20.09 | 0.52 |
| 587.04 | 649.37 | 507 | 329.85 | 363.39 | 308.15 | |
Revenue Growth (YoY) | 0.98% | 28.08% | 53.71% | -9.23% | 17.93% | 1.44% |
Cost of Revenue | 657.36 | 756.06 | 611.75 | 381.36 | 311.55 | 216.43 |
Gross Profit | -70.32 | -106.69 | -104.74 | -51.51 | 51.84 | 91.71 |
Selling, General & Admin | 59.22 | 61.05 | 54.06 | 38.16 | 37.29 | 29.79 |
Research & Development | 23.3 | 35.56 | 27.53 | 21.82 | 24.82 | 19.91 |
Other Operating Expenses | 9.53 | 7.08 | 4.4 | 3.86 | 2.97 | 3.79 |
Operating Expenses | 93.56 | 104.06 | 87.26 | 65.19 | 65.8 | 52.54 |
Operating Income | -163.87 | -210.75 | -192 | -116.7 | -13.96 | 39.17 |
Interest Expense | -60.37 | -62.06 | -37.1 | -16.22 | -2.81 | -0.98 |
Interest & Investment Income | 3.24 | 9.4 | 11.55 | 0.18 | 0.83 | 13.28 |
Currency Exchange Gain (Loss) | 2.62 | 2.62 | -0.56 | 2.1 | -1.23 | -3.8 |
Other Non Operating Income (Expenses) | 5.46 | -0.04 | -1.31 | -0.23 | -0.13 | -0.42 |
EBT Excluding Unusual Items | -212.93 | -260.84 | -219.42 | -130.88 | -17.31 | 47.25 |
Impairment of Goodwill | -61.6 | -61.6 | -12.7 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -10.12 | -20.56 | -3.03 |
Gain (Loss) on Sale of Assets | -3.8 | 0.04 | -0.04 | - | 0.01 | 0.07 |
Asset Writedown | -52.76 | -110.39 | -12.15 | -6.25 | -0.22 | - |
Other Unusual Items | 8.01 | 4.64 | 3.42 | 13.14 | 5.73 | 4.15 |
Pretax Income | -323.07 | -428.15 | -240.89 | -134.11 | -32.35 | 48.44 |
Income Tax Expense | 47.8 | 17.83 | -18.28 | -11.39 | -5.91 | 5.51 |
Earnings From Continuing Operations | -370.88 | -445.98 | -222.62 | -122.72 | -26.44 | 42.94 |
Minority Interest in Earnings | 0.41 | 1.11 | 0.8 | 0.78 | 0.4 | 0.27 |
Net Income | -370.47 | -444.86 | -221.82 | -121.94 | -26.04 | 43.21 |
Net Income to Common | -370.47 | -444.86 | -221.82 | -121.94 | -26.04 | 43.21 |
Net Income Growth | - | - | - | - | - | -24.15% |
Shares Outstanding (Basic) | 156 | 156 | 154 | 154 | 153 | 154 |
Shares Outstanding (Diluted) | 156 | 156 | 154 | 154 | 153 | 154 |
Shares Change (YoY) | 0.34% | 0.98% | -0.20% | 0.75% | -0.72% | 0.23% |
EPS (Basic) | -2.38 | -2.86 | -1.44 | -0.79 | -0.17 | 0.28 |
EPS (Diluted) | -2.38 | -2.86 | -1.44 | -0.79 | -0.17 | 0.28 |
EPS Growth | - | - | - | - | - | -24.32% |
Free Cash Flow | 66.48 | 16.35 | -651.3 | -146.15 | -322 | -163.07 |
Free Cash Flow Per Share | 0.43 | 0.10 | -4.23 | -0.95 | -2.10 | -1.06 |
Dividend Per Share | - | - | - | - | - | 0.140 |
Dividend Growth | - | - | - | - | - | 7.03% |
Gross Margin | -11.98% | -16.43% | -20.66% | -15.62% | 14.27% | 29.76% |
Operating Margin | -27.91% | -32.45% | -37.87% | -35.38% | -3.84% | 12.71% |
Profit Margin | -63.11% | -68.51% | -43.75% | -36.97% | -7.17% | 14.02% |
Free Cash Flow Margin | 11.33% | 2.52% | -128.46% | -44.31% | -88.61% | -52.92% |
EBITDA | -47.01 | -114.28 | -122.73 | -52.61 | 19.91 | 69.63 |
EBITDA Margin | -8.01% | -17.60% | -24.21% | -15.95% | 5.48% | 22.60% |
D&A For EBITDA | 116.86 | 96.47 | 69.28 | 64.09 | 33.87 | 30.45 |
EBIT | -163.87 | -210.75 | -192 | -116.7 | -13.96 | 39.17 |
EBIT Margin | -27.91% | -32.45% | -37.87% | -35.38% | -3.84% | 12.71% |
Effective Tax Rate | - | - | - | - | - | 11.37% |
Revenue as Reported | 587.04 | 649.37 | 507 | 329.85 | 363.39 | 308.15 |
Advertising Expenses | - | 0.53 | 0.44 | 0.8 | 2.03 | 1.4 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.